{
  "id": "adv_mhgap#screening_cues_ce7f6de9",
  "content": "antidepressant treatment, continuation of the antidepressant treatment\nshould be considered for at least six months after remission. Treatment\nshould be regularly monitored, with special attention to treatment\nadherence, change in depressive symptoms and possible adverse effects.\nStrength of recommendation: Conditional\nCertainty of evidence: Very low\nJustification average of relapse-free months over a year was\ny Two meta-analyses contributed to the evidence higher in the pharmacotherapy groups than in the\nprofile: Kato et al., 2021 (40 RCTs) (134); Zhou et al., placebo groups.\n2022 (40 RCTs) (135). One primary study (RCT) also y The certainty of evidence for the mean difference\ncontributed: Lewis et al., 2021 (136). in relapse rates between antidepressant medicines\ny Most of the difference in relapse rates (85.5%) and pill placebo from 0 to 9 months, and relapse-\nbetween pharmacotherapy and placebo occurred in free months at one year post-remission, response or\nthe first three months (63.9%) and first six months recovery, is very low.\n(another 22.6%). The difference in relapse-free rates y The certainty of evidence is low for relapse rates at\nbecomes much smaller after six months. six months post-remission between antidepressants\ny The relapse rate at one year was lower for and pill placebo.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General â€” Screening Cues antidepressant treatment, continuation of the antidepressant treatment\nshould be considered for at least six months after remission. Treatment\nshould be regularly monitored, with special attention to treatment\nadherence, change in depressive symptoms and possible adverse effects.\nStrength of recommendation: Conditional\nCertainty of evidence: Very low\nJustification average of relapse-free months over a year was\ny Two meta-analyses contributed to the evidence higher in the pharmacotherapy groups than in the\nprofile: Kato et al., 2021 (40 RCTs) (134); Zhou et al., placebo groups.\n2022 (40 RCTs) (135). One primary study (RCT) also y The certainty of evidence for the mean difference\ncontributed: Lewis et al., 2021 (136). in relapse rates between antidepressant medicines\ny Most of the difference in relapse rates (85.5%) and pill placebo from 0 to 9 months, and relapse-\nbetween pharmacotherapy and placebo occurred in free months at one year post-remission, response or\nthe first three months (63.9%) and first six months recovery, is very low.\n(another 22.6%). The difference in relapse-free rates y The certainty of evidence is low for relapse rates at\nbecomes much smaller after six months. six months post-remission between antidepressants\ny The relapse rate at one year was lower for and pill placebo. Antidepressant treatment, continuation of the antidepressant treatment\nshould be considered for at least six months after remission. treatment\nshould be regularly monitored, with special attention to treatment\nadherence,..."
}